PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
See full prescribing information for complete boxed warning.
- TRADE NAME: Adcetris (Seattle Genetics)
- INDICATIONS: Hodgkin's lymphoma, systemic anaplastic large cell lymphoma
- CLASS: Antibody-drug conjugate (ADC), CD30-directed antibody-drug conjugate, Monoclonal antibody
- HALF-LIFE: 4–6 days
- FDA APPROVAL DATE: 11/16/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bleomycin, Efavirenz, Ketoconazole, Rifampin, Strong CYP3A4 inhibitors
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of brentuximab vedotin in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/27/2024
